Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
post one pr since October providing info on testing related to the IND that was rejected by the FDA......
there are none......PMCB has done nothing in seven months
will PMCB be trading .50 on April 15th?
Well when AMC is trading at 25.00 on the buyout maybe us longs will be happy and the shorts will be gone
what are the requirements for PMCB to be listed on the NASDAQ? please list them
is one of them to have the IND rejected by the FDA?
what trials? there are none IND has been rejected by the FDA.....so no trials
1 Year Stability Study meaningless not part of why FDA rejected PMCBs IND
what are the requirement for PMCB to be listed on the NASDAQ please list them
Thanks
Im looking for next week to be the same as every week for 21 years has been for PMCB come Monday. Enjoy the weekend shorts.
April 15th past again for PMCB
reading and understanding the 10Q is very important
WRONG WRONG WRONG
read the pr and the 10Q by kenny
PMCB has not addressed one issue on the FDA rejected IND list in 7 months
PMCB IND rejected by the FDA and put on hold
yes if ind was accepted it wouldn't be on hold which is a rejection
PMCB IND rejected by the FDA in 3 days
It’s important to read things clearly taking into account every word.
read the pr or the 10Q
Post a link where the fda accepted the ind
FDA rejected PMCBs IND and place it on hold....thats how it works
PharmaCyte Biotech Successfully Completes 1 Year Stability Study with is not a part of why the FDA rejected the IND
I will make another 400K and my son will 500k and we will buy matching jets skis go PMCB
PMCBs IND has been rejected by the FDA PMCB has not addressed and issues by the FDA in 7 months
those are the facts
FDA has rejected PMCBs IND and put it on hold
and after seven months PMCB had not addressed one issue
Once again...PMCB IND rejected by the FDA in 3 days read the 10Q its right there
FDA rejected PMCBs IND pr is meaningless will do nothing to get IND approved
key word scientist.....not penny stock lawyer
PharmaCyte Biotech IND rejected by the FDA......so Stability Study meaningless not on the FDA list
when will Hidalgo be held accountable for this misleading statement
Hidalgo has no integrity pay him and he will say anything
meaningless PR from kenny
PMCB has not completed one task the FDA wants......the FDA rejected PMCBs IND never to be heard of again
kenny who did the study? lets see the study I guarantee he can't produce it
is PMCBs IND still rejected by the FDA?
Are you Jealous?? ;.))
FDA has rejected PMCBs IND so there won't be any clinical trials
Wrong wrong couldn’t be wronger
it was being done before IND and does not address why the FDA rejected PMCBs IND
todays PR is meaningless kenny been pumping this every 3 month
FDA rejected PMCBs IND with this test
08 JUL 20
LAGUNA HILLS, CA, July 8, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the three-month product stability testing that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ and CypCaps™ passed all of the FDA-required tests. This is the final product that will be used in the company’s planned clinical trial in locally advanced, inoperable pancreatic cancer.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said of the completed three-month stability study, “We are pleased to announce that our Cell-in-a-Box® encapsulated cell product CypCaps™ has passed all of the FDA-required tests for the first three-months of a 24-month stability study. This is part of an ongoing study to determine the shelf life of the CypCaps™ final product that the FDA requires for all medical products. The data will be included in our IND. All future longer-term shelf life analyses, such as the next one at six months post-production, will be reported to the FDA but is not required for PharmaCyte to submit an IND.”
As based in the ICH guidelines, regulatory agencies around the world, including the FDA, require a shelf-life determination for all medical products. Living products, like cell therapies such as CypCaps™, as well as live vaccines etc., are particularly sensitive and more prone to inactivation over time, so it is especially important to determine the shelf-life for these products.
A battery of tests was performed on CypCaps™ that had been frozen post-production for three months of storage at -80C. Samples were thawed to show that the cells inside the CypCaps™ were still alive and functional as well as free of infectious agents. Some of these tests were performed by Austrianova (cell count, biological activity of the cells, capsule integrity, label integrity), whereas others (sterility, pH measurement) were performed by contract labs.
To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer
stability testing required by the U.S. Food and Drug Administration......this was not one of the reason for the fda rejecting the IND.......This was being done before IND was submitted......another smoke screen
FDA has rejected PMCBs IND.......it over 6 months since the rejection PMCB has not addressed one issue
PMCBs ceo has been MIA since and is either afraid or unwilling tp address shareholders